Drug details
Skyrizi (risankizumab-rzaa injection)
type of Monoclonal Antibodies, Antipsoriatics, Systemic, Interleukin Inhibitors
Skyrizi (risankizumab-rzaa) is an interleukin-23 antagonist indicated for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
This drug may have the following side effects:
- loss of appetite,
- rash,
- diarrhea,
- fever,
- night sweats,
- easy bruising,
- unusual bleeding,
- pale skin,
- shortness of breath,
- chills,
- body aches,
- stomach pain,
- sweating,
- cough,
- increased urination,
- mouth sores,
- red or swollen gums,
- weight loss, and
- burning when you urinate,
- changes in skin color,
- feeling very tired
- bloody mucus,
- skin sores from psoriasis,
- redness, blisters, itching, burning, cracking or peeling of the skin,
The following drugs are related to Skyrizi, either as a replacement or used together:
- Adbry (tralokinumab-ldrm for injection)
- Otezla (apremilast tablets)
- Imuran (azathioprine)
- Wynzora (calcipotriene and betamethasone dipropionate cream)
- Cimzia (certolizumab pegol injection)
- Olux (clobetasol propionate)
- Olux-E (clobetasol propionate foam)
- Eucrisa Ointment (crisaborole)
- Sotyktu (deucravacitinib tablets)
- Duobrii (halobetasol propionate and tazarotene lotion)
- Enbrel (etanercept)
- Simponi Aria (golimumab for infusion)
- Simponi Injection (golimumab injection)
- Plaquenil (hydroxychloroquine)
- Ilumya (tildrakizumab-asmn injection, for subcutaneous use)
- Remicade (infliximab)
- Taltz (ixekizumab injection, for subcutaneous use)
- Kimyrsa (oritavancin for injeciton)
- Rinvoq (upadacitinib extended-release tablets)
- Zoryve (roflumilast cream)
- Stelara Injection (ustekinumab)
- Vtama (tapinarof cream)
- Tofidence (tocilizumab-bavi injection)
- Xeljanz (tofacitinib tablets)